Stan Schroeder, PresidentZyme Fast is changing conventional infection treatment through a targeted, antibiotic-free pathogen removal strategy. Its cost-effective, regenerative molecules for gastrointestinal infections, skin health, cosmetics and animal care are redefining how precision biotechnology can address some of healthcare’s most persistent challenges.
Built on vaccine manufacturing expertise, it develops targeted vaccines against specific pathogens and deploys them in avians, whose immune systems produce egg yolk passive immunity antibodies. These antibodies are then administered to selectively remove harmful bacteria, viruses and fungi from the gut without disrupting the broader microbiome.
“Instead of blowing everything up with dynamite and killing everything in the vicinity, we can simply cherry-pick what we want to get out of there,” says Stan Schroeder, president.
Zyme Fast’s antibody platform also supports rapid pathogen identification systems designed to confirm targeted infections before treatment.
Replacing Broad-Spectrum Antibiotics With Targeted Immunity
Central to Zyme Fast’s expertise is its ability to identify and neutralize the specific virulence factors responsible for pathogenic activity. Most bacteria rely on surface proteins or adhesion mechanisms that allow them to anchor themselves within the gut lining.
Instead of blowing everything up with dynamite and killing everything in the vicinity, we can simply cherry-pick what we want to get out of there.
To support large-scale antibody production, Zyme Fast operates subsidiary facilities in China, including a laying-hen operation capable of producing raw materials for commercial-scale manufacturing. It can process up to one million eggs per day.
“The future of medicine is moving toward precision pathogen removal,” says Schroeder.
Zyme Fast’s precision-based strategy has already led to several notable developments in human health applications. Among the most significant targets is Clostridioides difficile (C. diff), one of the world’s most dangerous antibiotic-resistant hospital superbugs. C. diff accounts for around 500,000 reported infections and nearly 30,000 deaths annually, costing the U.S. healthcare system $7.8 billion each year.
Another major focus area is Helicobacter pylori (H. pylori), the bacterium responsible for 95 percent of gastric ulcers and approximately 76 percent of gastric cancers worldwide. With nearly half of the global population estimated to carry H. pylori, Zyme Fast’s antibodies are a perfect solution.
It has also developed antibodies targeting E. coli O157:H7, commonly known as “hamburger disease,” which has been linked to severe outbreaks in both Canada and the U.S.
Unlocking Affordable Regenerative and Cosmetic Biotechnology
During the development of its vaccine production technologies, Zyme Fast created a proprietary, small-molecule production platform used to manufacture the proteins required for its antibody and vaccine work. Recognizing the broader commercial potential of this capability, it expanded into skin health and cosmetics by producing epidermal growth factor (EGF), fibroblast growth factor (FGF) and superoxide dismutase (SOD)—three molecules increasingly recognized for their role in skin regeneration, wound healing and anti-aging applications.
Traditionally, these proteins have been prohibitively expensive. Research-grade EGF sold for nearly $800,000 per gram and cosmetic-grade EGF at approximately $300,000 per gram. Zyme Fast’s proprietary production platform reduces manufacturing costs by a factor of 20 or more. This improves commercial viability, expands market accessibility, and enables more effective product formulations.
EGF has emerged as a sought-after ingredient in cosmetics, such as anti-aging and skin rejuvenation products, because of its role in stimulating cellular renewal. FGF contributes to fibroblast production, a vital part of skin repair while SOD acts as a powerful antioxidant capable of combating oxidative stress. The combination has demonstrated the ability to reduce fine lines, wrinkles and other visible signs of aging.
Its skin health research has revealed broader therapeutic potential. Demonstrations conducted using its protein combinations have shown promising results in conditions such as eczema, psoriasis, rosacea, diabetic ulcers and burns, as well as in wound healing. As awareness around regenerative skin therapies continues to expand, Zyme Fast sees substantial long-term opportunity in this sector.
Scaling Across Diverse Healthcare Markets
Animal health is another major pillar. The overuse of antibiotics in livestock production has become one of the leading contributors to global antibiotic resistance. In Canada alone, the majority of prescribed antibiotics are used within the animal sector. Zyme Fast’s passive immunity products aim to provide livestock producers with a targeted alternative that avoids the resistance cycle created by repeated antibiotic exposure.
-
The future of medicine is moving toward precision pathogen removal.
Early successes involved developing a passive immunity antibody for F4 E. coli, previously known as K88, a dangerous bacterium affecting piglets between seven and 28 days old. The bacteria use a fimbria to insert into receptors in the gut lining, where they signal each other and create toxins. This can result in death in up to 30 percent of infected populations. Zyme Fast neutralizes fimbria to prevent the bacteria from colonizing.
More than 25 passive immunity antibodies are maintained in its pipeline for animal applications. Zyme Fast continues to view animal health as a critical long-term growth segment, despite market disruptions such as African swine fever.
Rapid Diagnostics for Targeted Infection Management
Rapid infection testing is a vital part of its technology platform. The antibodies it produces allow for the creation of rapid lateral flow assay tests similar to widely used COVID-19 test kits. Designed for pathogens such as C. diff and H. pylori, the simple and inexpensive tests can confirm within five minutes whether a person is infected with a specific bacterium, eliminating the need for lengthy and expensive laboratory testing.
For instance, in hospital settings, symptoms such as diarrhea could result from multiple causes, including Salmonella, E. coli or C. diff. Using a rapid lateral flow assay test, healthcare providers can identify within five minutes whether the infection is specifically C. diff and immediately start the corresponding antibody treatment.
The rapid testing and targeted treatment form a “one-two combination” strategy—identifying the pathogen and then rapidly removing it using passive immunity antibodies.
Shaping a Future Beyond Antibiotic-Driven Treatment Models
As Zyme Fast advances targeted passive immunity technologies beyond conventional antibiotic-driven treatment models, it continues navigating the slower adoption cycles often associated with emerging medical approaches. Because targeted pathogen removal remains unfamiliar to many healthcare professionals and researchers, broader acceptance still depends on continued clinical validation, education and regulatory progress.
During a presentation involving infectious disease experts in Africa, where Zyme Fast is exploring initiatives targeting five bacteria linked to the deaths of nearly two million children annually, questions surrounding toxicity testing highlighted the caution that often accompanies unfamiliar therapeutic technologies. Despite egg yolk antibodies being naturally present in eggs consumed for thousands of years, the use of targeted passive immunity antibodies as a therapeutic platform remains relatively new within mainstream medical adoption.
“It took many years for antibiotics to become widely accepted in medicine. Targeted pathogen removal platform faces a similar adoption curve,” says Schroeder.
Zyme Fast is currently focused on securing additional funding and advancing product registration efforts to support future commercialization.
As research into the gut microbiome accelerates, Zyme Fast plans to extend future applications of its technology well beyond gastrointestinal infections. Emerging studies increasingly suggest links between gut bacteria and conditions such as Parkinson’s disease, multiple sclerosis, Crohn’s disease, irritable bowel syndrome, and even mood swings. Much of this research remains in early stages, but Zyme Fast sees an expanding pipeline of opportunities as scientists continue identifying microbial contributors to chronic disease.
Zyme Fast has been recognized as the Top Human Health Biotechnology Company in Canada 2026 for its work in advancing precision-targeted passive immunity technologies designed to address antibiotic resistance.
As research continues to uncover the broader role of the microbiome in human health, Zyme Fast is positioning targeted pathogen removal as a more selective alternative to conventional, antibiotic-driven treatment models.
Email: s.schroeder@zymefast.com
Precision over Suppression: The Next Phase of Human Health Biotechnology
Antibiotic resistance has shifted infection management into a space where traditional approaches no longer provide dependable resolution. Broad-spectrum treatments, once considered reliable, now introduce a secondary problem: disruption of the gut microbiome that often leads to recurrence, complications or prolonged recovery cycles. Decision-makers evaluating human health biotechnology solutions are increasingly forced to weigh not just whether a pathogen can be eliminated, but how that elimination affects the surrounding biological system. Interventions that solve one problem while destabilizing another no longer meet the threshold for clinical or economic viability, particularly in environments where patient outcomes are tied to long-term systemic stability rather than short-term suppression.
Persistent infections amplify this tension in ways that extend beyond individual treatment episodes. Organisms such as C. difficile and H. pylori continue to impose significant burdens due to their ability to survive treatment cycles and re-emerge under favorable conditions. Recurrence is not simply a clinical inconvenience; it signals that the underlying method of intervention fails to isolate the root cause with sufficient precision. Solutions that can directly target the causative agent, rather than cycling through successive treatments, shift the equation from management to resolution. This distinction has become central to how healthcare systems assess long-term value, particularly when repeated interventions increase both cost exposure and patient risk.
Another constraint lies in how treatments interact with natural biological processes. Methods that override the body’s systems often introduce variability in outcomes, especially when patient responses differ across demographics or underlying conditions. In contrast, approaches that work within existing biological pathways tend to offer greater predictability and fewer unintended consequences. Passive immunity models have drawn increasing attention in this context, particularly those capable of delivering targeted effects without triggering systemic disruption. The ability to act selectively while maintaining microbiome stability reflects a broader transition toward interventions that prioritize balance, specificity and sustained effectiveness.
“The future of infection treatment is not just killing pathogens. It is doing so without disrupting the body’s natural balance.”
Zyme Fast aligns closely with these evolving expectations through a model centered on targeted pathogen removal without antibiotic use. Its approach leverages egg yolk-derived antibodies that identify and eliminate specific bacteria, viruses or fungi in the gut while leaving surrounding microbial populations intact. This selective mechanism addresses organisms such as C. difficile, H. pylori and certain E. coli strains, offering a path to resolution that avoids the recurrence patterns commonly associated with conventional treatments.
"Zyme Fast offers a smarter path to infection control through precise, microbiome-friendly pathogen removal."
Its method is grounded in identifying pathogen-specific virulence factors, cloning them and using them to generate precise antibody responses. This allows the intervention to focus exclusively on harmful organisms rather than affecting the broader microbiome. The result is a targeted treatment profile that reduces systemic impact while maintaining effectiveness. Its ability to act within a limited number of doses further strengthens relevance in settings where prolonged treatment cycles introduce cost pressures and patient compliance challenges, particularly in hospital or outpatient care environments.
Zyme Fast’s focus on biological specificity, combined with a delivery model that integrates naturally into the body’s processes, positions it as a strong choice for organizations seeking alternatives to conventional antibiotic-driven approaches.
...Read more
Human Health Biotechnology Companies in Canada Info
Q1
What Should Readers Know About Human Health Biotechnology in Canada?
Human Health Biotechnology in Canada covers science-led products aimed at real health problems, not just laboratory promise. In this category, the strongest work often connects biology, manufacturing know-how and practical treatment goals. For gastrointestinal disease, that can mean products designed to address specific pathogens, reduce infection burden and support better patient recovery without relying only on traditional drug approaches. The science has to travel from the bench into repeatable production, careful testing and plain patient-facing claims.
Q2
How Does Zyme Fast Bring Biotech Science Into Human Health?
Gastrointestinal infections-hospital and food-acquired-generate problematic, expensive, painful care. Zyme Fast functions in the Human Health Biotechnology space in Canada using recombinant technology, as well as pathogen-specific development for such organisms as C. Difficile, E. Coli O157:H7, and H. Pylori. Its company, established in 2001, positions its products as preventive and therapeutic, showing positive in vitro and/or in vivo results for portions of its pipeline, with human trials yet to be conducted for important applications.
Q3
Why Do Gastrointestinal Health Therapies Need a Different Approach?
Gut infections can move quickly from discomfort to serious medical complications, especially when bacteria produce toxins or resist standard treatment. Human Health Biotechnology in Canada matters here because targeted biological products can be designed around the pathogen, rather than broad suppression alone. The practical test is whether a therapy can be specific, safe, scalable and clear about what still needs clinical validation. Patients, hospitals and product partners all need that distinction before a promising platform becomes a usable health product.
Q4
What Role Do Peptides Play in Skin Repair and Wellness?
Peptides can be thought of as signaling molecules that are beneficial in human health and cosmetic applications when made with consistent quality. Human Health Biotechnology in Canada includes efforts regarding molecules like epidermal growth factor, fibroblast growth factor, and superoxide dismutase. These ingredients are linked to skin repair, antioxidant support and activity of collagen and elastin, although producers need to be held accountable and distinguish cosmetic potential from medical treatment. Clear labelling and expectations need to be maintained because the same molecules can be considered by both parties.
Q5
How Do Zyme Fast’s Production Capabilities Affect Its Biotechnology Model?
Biotech ideas often stall when production is too costly or too difficult to scale. Zyme Fast links Human Health Biotechnology in Canada to a broader production model, including a Manitoba R&D base and facilities in China. Its Changsha operation includes egg-processing capacity and quality systems for antibody-rich products, while its proprietary production methods are presented as a way to reduce the cost of high-demand molecules. The company also points to a leadership team with deep biotech, sales and product-development experience.
Q6
What Should Decision-Makers Look For in This Category?
Decision-makers should look beyond scientific language and ask how the product works, what evidence supports it and where it sits in the development pathway. Human Health Biotechnology in Canada should be judged by specificity, safety review, production discipline, regulatory readiness and honest communication about limits. A strong evaluation also checks whether the same platform can support diagnostics, prevention or treatment without blurring those roles. The best review uses real use cases, such as a hospital infection pathway or pathogen test workflow, not only a polished product summary.
